Evidence map›Paper›PMID 33841008›Full record

ArticleJournal of ginseng research2021

Anti-tumor activities of

Shan He, Fangqiao Lyu, Lixia Lou, Lu Liu, Songlin Li, Johannes Jakowitsch, Yan Ma

Open access · goldAbstract read
In one paragraph

Article in Journal of ginseng research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Anti-Colorectal Cancer Activity ofInternational journal of molecular sciences · 2025
    Review
  6. Article
  7. The beneficial potential of ginseng for menopause.Journal of ginseng research · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Frontiers in pharmacology · 2022
    Article
  13. Evaluation of theFrontiers in chemistry · 2022
    Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Shan HeDepartment of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology & Immunology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Fangqiao LyuDepartment of Cell Biology, School of Basic Medicine, Capital Medical University, Beijing, China.
Lixia LouThe Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Lu LiuBeijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Songlin LiDepartment of Pharmaceutical Analysis and Metabolomics, Jiangsu Province Academy of Traditional Chinese Medicine and Jiangsu Branch of China Academy of Chinese Medical Sciences, Nanjing, China.
Johannes JakowitschDepartment of Internal Medicine, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Yan MaDepartment of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology & Immunology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Capital Medical University · CNMedical University of Vienna · ATBeijing University of Chinese Medicine · CNChina Academy of Chinese Medical Sciences · CNVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate carcinoma is the second most common cancer among men worldwide. Developing new therapeutic approaches and diagnostic biomarkers for prostate cancer (PC) is a significant need. The Chinese herbal medicine

methodsWe used the human PC cell line DU145 and the prostate epithelial cell line PNT2 to perform cell viability assays, flow cytometric analysis of the cell cycle, and FACS-based apoptosis assays. Microarray-based gene expression analysis was used to display specific gene expression patterns and to search for novel biomarkers. Western blot and quantitative real-time PCR were performed to demonstrate the expression levels of multiple cancer-related genes.

resultsOur data showed that PQS inhibited the viability of DU145 cells and induced cell cycle arrest at the G1 phase. A significant decrease in DU145 cell invasion and migration were observed after 24 h treatment by PQS. PQS up-regulated the expression levels of p21, p53, TMEM79, ACOXL, ETV5, and SPINT1 while it down-regulated the expression levels of bcl2, STAT3, FANCD2, DRD2, and TMPRSS2.

conclusionPQS promoted cells apoptosis and inhibited the proliferation of DU145 cells, which suggests that PQS may be effective for treating PC. TMEM79 and ACOXL were expressed significantly higher in PNT2 than in DU145 cells and could be novel biomarker candidates for PC diagnosis.

Indexed as

ACOXL, Acyl-CoA oxidase-like proteinbcl2, B-cell lymphoma 2Chinese medicinal herbsDRD2, dopamine receptor D2ETV5, ETS variant 5FACS, fluorescence-activated cell sortingFANCD2, fanconi anemia group D2p21, cyclin-dependent kinase inhibitor p21p53, tumor suppressor p53Panax quinquefoliusPC, prostate cancerPotential biomarkersPQS, Panax quinquefolius saponinsProstate cancer cellsqRT-PCR, quantitative real-time PCRsaponinsSPINT1, serine peptidase inhibitor Kunitz type 1STAT3, signal transducer and activator of transcription 3TCM, Traditional Chinese MedicineTMEM79, transmembrane protein 79TMPRSS2, transmembrane protease serine 2

Identifiers

PMID33841008
PMCPMC8020356
OpenAlexW2761936731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.